| Literature DB >> 26229004 |
Michelle Dawes1, Kelli J Kochan2, Penny K Riggs2, J Timothy Lightfoot3.
Abstract
Despite established health benefits of regular exercise, the majority of Americans do not meet the recommended levels of physical activity. While it is known that voluntary activity levels are largely heritable, the genetic mechanisms that regulate activity are not well understood. MicroRNAs (miRNAs) are small non-coding RNAs that inhibit transcription by binding to a target gene, inhibiting protein production. The purpose of this study was to investigate differential miRNA expression between inherently high- (C57L/J) and low- (C3H/HeJ) active inbred mice in soleus, extensor digitorum longus (EDL), and nucleus accumbens tissues. Expression was initially determined by miRNA microarray analysis, and selected miRNAs were validated by qRT-PCR. Expression of 13 miRNAs varied between strains in the nucleus accumbens, 20 in soleus, and eight in EDL, by microarray analysis. Two miRNAs were validated by qRT-PCR in the nucleus accumbens; miR-466 was downregulated (~4 fold; P < 0.0004), and miR-342-5p was upregulated (~115 fold; P < 0.0001) in high-active mice. MiR-466 was downregulated (~5 fold; P < 0.0001) in the soleus of high-active mice as well. Interestingly, miR-466 is one of several miRNA families with sequence located in intron 10 of Sfmbt2; miRNAs at this locus are thought to drive imprinting of this gene. "Pathways in cancer" and "TGFβ signaling" were the most significant pathways of putative target genes in both the soleus and nucleus accumbens. Our results are the first to consider differential miRNA expression between high- and low-active mice, and suggest that miRNAs may play a role in regulation of physical activity.Entities:
Keywords: miRNA; physical activity; wheel running
Year: 2015 PMID: 26229004 PMCID: PMC4552544 DOI: 10.14814/phy2.12469
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
miRNA associations and qRT-PCR assay information
| miRNA family | Tissue miRNA evaluated in | miRNA validated by qPCR | Name of assay validated | Taqman assay ID |
|---|---|---|---|---|
| Small nuclear RNA | All | U6 | miRNA, U6 snRNA | 001973 |
| mir-99 | All | miR-99b-5p | hsa-miR-99b-5p | 000436 |
| mir-466 | NA | miR-466d-3p | mmu-miR-466d-3p | 002535 |
| Soleus | miR-466b-3p | mmu-miR-466p-3p | 464896 mat | |
| mir-342 | NA | miR-342-5p | mmu-miR-342-5p | 002527 |
| mir-1960 | Soleus | miR-1960 | mmu-miR-1960 | 121148 mat |
Describes the miRNA family of origin, tissue in which each miRNA was evaluated by qRT-PCR, and the name and Taqman ID of specific assay validated. Human miRNA 99b-5p was utilized as a control miRNA. MiR-466p-3p assay was used as miR-466b-3p in the soleus. Finally, as miR-466d-3p and miR-466b-3p are 100% matching, they are noted under the same miRNA family and referred to as simply miR-466 regardless of tissue of reference.
Variability of U6 and miR-99b as reference assays
| Variability of U6 and miR-99b as reference assays | ||||
|---|---|---|---|---|
| hsa-miR-99b | U6 | |||
| C of V | C of V | |||
| Nucleus accumbens | 0.69 | 0.40 | 0.024 | 0.71 |
| EDL | 0.64 | 0.22 | 0.13 | 0.86 |
| Soleus | 0.23 | 0.23 | 0.09 | 0.21 |
The P-value and coefficient of variation (CoV) for each tissue using miR-99b and U6 as endogenous reference miRNAs. Hsa-miR-99b-5p proved an adequate control assay for all three tissues, not differing in expression between strains within tissues. Although U6 was shown to be similar between strains in the soleus, it was different between strains in the nucleus accumbens. The CoV was greater, in general, when using U6 as the reference miRNA, providing additional support for the use of miR-99b as our endogenous reference miRNA.
Significantly different expression, P < 0.05.
Differentially expressed miRNAs between high- and low-active mice
| Systematic name | Regulation (high vs low) | Fold change | Active sequence | Chr | Mirbase accession No | Positon on chr | Strand | Stop position on chr | |
|---|---|---|---|---|---|---|---|---|---|
| Nucleus Accumbens | |||||||||
| mmu-miR-3095-3p | <0.001 | Up | 104 | AAAAGCTCTCTCTCCAGT | Chr4 | MIMAT0014912 | 58453959 | + | 58453943 |
| mmu-miR-342-3p | <0.001 | Up | 4 | ACGGGTGCGATTTCTGT | Chr12 | MIMAT0000590 | 109896897 | − | 109896912 |
| | <0.001 | CTCAATCACAGATAGCACC | Chrl2 | MIMAT0004653 | 109896852 | − | 109896869 | ||
| mmu-miR-375 | 0.03 | Down | 4 | TCACGCGAGCCGAACG | Chr1 | MIMAT0000739 | 74947292 | + | 74947278 |
| mmu-miR-376c | <0.01 | Up | 3 | ACGTGAAATTTCCTCTATGTT | Chrl2 | MIMAT0003183 | 110960981 | − | 110961000 |
| | <0.001 | CTATGTGTGCGTGTAT | Chr2 | MTMAT0004931 | 10433650 | − | 10433664 | ||
| mmu-miR-467a | <0.01 | Down | 4 | TGTAGGTGTGTGTATGTATA | Chr2 | MTMAT0002108 | 10398019 | − | 10398038 |
| mmu-miR-467b | <0.01 | Down | 3 | CATATACATGCAGGCACT | Chr2 | MIMAT0005448 | 10402887 | − | 10402903 |
| mmu-miR-467 c | <0.001 | Down | 87 | CACATATACATGCACGCAC | Chr2 | MTMAT0004885 | 10395572 | − | 10395589 |
| mmu-miR-5117 | <0.001 | Up | 191 | TAACTTTATTGATCATCACTAAC | Chr1 | MIMAT0020625 | 162967492 | − | 162967513 |
| mmu-miR-669f-3p | <0.01 | Down | 2 | ATACGTGTGTGTGTATGT | Chr2 | MTMAT0005839 | 10388917 | − | 10388934 |
| mmu-miR-6691 | <0.001 | Down | 194 | ACATATACATGCACACAC | Chr2 | MIMAT0009418 | 10390015 | − | 10390032 |
| mmu-miR-669n | <0.01 | Down | 3 | ACACACATCCACACACAA | Chr2 | MIMAT0009427 | 10430950 | − | 10430967 |
| EDL | |||||||||
| mmu-miR-1957 | <0.001 | Down | 237 | GTCATATGCTCTACCACT | Chr4 | MTMAT0009430 | 118802399 | − | 118802415 |
| mmu-miR-1966 | <0.001 | Down | 80 | GACTCTCTCCTGAGCC | Chr8 | MTMAT0009439 | 108139391 | − | 108139405 |
| mmu-miR-1967 | <0.001 | Down | 68 | GCATCTTCTCCCCAG | Chr8 | MTMAT0009440 | 126546597 | − | 126546610 |
| mmu-miR-205 | <0.001 | Down | 326 | CAGACTCCGGTGGAAT | Chr1 | MIMAT0000238 | 195333684 | + | 195333670 |
| mmu-miR-3091-5p | <0.001 | Up | 50 | GCGGGCCCAACC | Chr2 | MIMAT0014903 | 179992262 | − | 179992272 |
| mmu-miR-342-3p | 0.02 | Up | 5 | ACGGGTGCGATTTCTGT | Chrl2 | MIMAT0000590 | 109896897 | − | 109896912 |
| mmu-miR-5117 | <0.001 | Up | 120 | TAACTTTATTGATCATCACTAAC | Chr1 | MTMAT0020625 | 162967492 | − | 162967513 |
| mmu-miR-5118 | <0.001 | Down | 54 | ACCAGGCTGGCCTA | Chrl6 | MIMAT0020626 | 55494889 | − | 55494901 |
| Soleus | |||||||||
| mmu-miR-148a | 0.02 | Down | 2 | ACAAAGTTCTGTAGTGCACT | Chr6 | MIMAT0000516 | 51219892 | + | 51219874 |
| mmu-miR-1843-5p | <0.001 | Down | 52 | AGTCAGACAGAGACCTC | Chr12 | MIMAT0014805 | 81492623 | + | 81492608 |
| mmu-miR-1927 | <0.001 | Down | 220 | TCAGTCCCTAACATCCA | Chr1 | MIMAT0009390 | 162226082 | + | 162226067 |
| mmu-miR-193 | <0.001 | Down | 80 | TCATCTTGCCCGCA | Chr11 | MIMAT0004544 | 79525486 | − | 79525498 |
| | AGCCCTCTTCTAACAGC | Chr5 | MIMAT0009433 | 30497297 | − | 30497312 | |||
| mmu-miR-299 | <0.001 | Down | 22 | AAGCGGTTTACCGTCCC | Chrl2 | MTMAT0004577 | 110948892 | − | 110948907 |
| mmu-miR-3 26 | <0.001 | Down | 42 | ACTGGAGGAAGGGCCCA | Chr7 | MIMAT0000559 | 106700843 | − | 106700858 |
| mmu-miR-342-3p | <0.001 | Up | 5 | ACGGGTGCGATTTCTGT | Chrl2 | MIMAT0000590 | 109896897 | − | 109896912 |
| mmu-miR-3 62-5p | <0.001 | Down | 31 | ATTCACACCTAGGTTCCA | ChrX | MTMAT0000706 | 6819135 | + | 6819119 |
| mmu-miR-376a | <0.001 | Down | 79 | ACGTGGATTTTCCTCTA | Chrl2 | MIMAT0000740 | 110962039 | − | 110962054 |
| mmu-miR-431 | <0.001 | Down | 42 | TGCATGACGGCCTGC | Chrl2 | MIMAT0001418 | 110828676 | − | 110828689 |
| | TCTTATGTGTGCGTGTA | Chr2 | MIMAT0004876 | 10395901 | − | 10395917 | |||
| mmu-miR-467 a | <0.001 | Down | 169 | TGTAGGTGTGTGTATGTATA | Chr2 | MIMAT0002108 | 10398019 | − | 10398038 |
| mmu-miR-467b | <0.001 | Down | 227 | CATATACATGCAGGCACT | Chr2 | MIMAT0005448 | 10402887 | − | 10402903 |
| mmu-miR-467e | <0.001 | Down | 73 | ACATATACATGCTCACACT | Chr2 | MIMAT0005293 | 10427362 | − | 10427379 |
| mmu-miR- 5103 | <0.001 | Down | 59 | CCTCAGGGGATCCC | Chr1 | MIMAT0020610 | 34490035 | + | 34490023 |
| mmu-miR- 5117 | <0.001 | Up | 204 | TAACTTTATTGATCATCACTAAC | Chr1 | MIMAT0020625 | 162967492 | − | 162967513 |
| mmu-miR-582-5p | <0.001 | Down | 69 | AGTAACTGGTTGAACAACTGTA | Chrl3 | MIMAT0005291 | 110114949 | − | 110114969 |
| mmu-miR-711 | <0.001 | Down | 44 | CTTACATCTCTCCCCG | Chr9 | MIMAT0003501 | 108872022 | − | 108872036 |
| mmu-miR-99a | <0.001 | Down | 40 | AGACCCATAGAAACGAGC | Chrl6 | MIMAT0016981 | 77599226 | − | 77599242 |
Differentially expressed miRNAs (P < 0.05) between high- (C57L/J) and low-active (C3H/HeJ) mice strains in nucleus accumbens, EDL, and soleus.
“P(corr)” refers to adjusted P -value after multiple testing correction; fold change is adjusted for multiple testing correction.
“Active sequence” is the probe sequence, “strand” refers to sense (+) or anti-sense (−) strand on which miRNA sequence is located. “Chr” refers to the chromosome on which the miRNA is located. Bold miRNAs were selected for validation by qRT-PCR. Highlighted miRNAs in nucleus accumbens and soleus are located in proximal end of Chr. 2.
Housekeeping miRNA.
Chromosome number of miRNA.
Figure 1Relative expression determined by qRT-PCR of (A) miR-342-5p (P < 0.0001) and (B) miR-466 (P < 0.0004) in nucleus accumbens and (C) miR-466 (P < 0.0001) and (D) miR-1960 (P = 0.06) in the soleus between high- (C57L/J) and low- (C3H/HeJ) active mice. *denotes differential expression. Relative expression is mean ± standard deviation.
KEGG pathways and GO terms for soleus putative target genes
| No. of genes included | % of genes included | ||
|---|---|---|---|
| KEGG pathways for putative target genes - soleus | |||
| Pathways in cancer | 19 | 4.4 | 3.50E-02 |
| TGF-beta signaling pathway | 9 | 2.1 | 4.20E-02 |
| Cell cycle | 10 | 2.3 | 8.70E-02 |
| Renal cell carcinoma | 7 | 1.6 | 1.30E-01 |
| Ubiquitin mediated proteolysis | 8 | 1.9 | 5.60E-01 |
| Progesterone-mediated oocyte maturation | 6 | 1.4 | 5.80E-01 |
| Cytokine-cytokine receptor interaction | 11 | 2.6 | 5.70E-01 |
| Toll-like receptor signaling pathway | 6 | 1.4 | 6.80E-01 |
| Endocytosis | 9 | 2.1 | 7.00E-01 |
| Adherens junction | 5 | 1.2 | 6.90E-01 |
| Type II diabetes mellitus | 4 | 0.9 | 6.80E-01 |
| GO terms for putative target genes - soleus | |||
| Vasculature development | 14 | 3.3 | 1.90E-01 |
| Blood vessel development | 13 | 3 | 2.70E-01 |
| Blood vessel morphogenesis | 11 | 2.6 | 3.30E-01 |
| Regulation of cellular response to stress | 6 | 1.4 | 4.10E-01 |
| Angiogenesis | 8 | 1.9 | 4.60E-01 |
| Hemopoiesis | 12 | 2.8 | 4.60E-01 |
| Muscle tissue development | 8 | 1.9 | 4.80E-01 |
| Regulation of vasoconstriction | 3 | 0.7 | 4.80E-01 |
| Muscle organ development | 9 | 2.1 | 5.40E-01 |
| Striated muscle tissue development | 7 | 1.6 | 6.10E-01 |
Predicted pathways and gene ontology (GO) terms of differentially expressed miRNA target genes from soleus analyzed through DAVID. No. of genes and percent of genes; number of genes out of all putative target genes generated through Genespring software included in respective KEGG pathway or GO term category.
KEGG pathways and GO terms for nucleus accumbens putative target genes
| No. of genes included | % of genes included | ||
|---|---|---|---|
| KEGG pathways for putative target genes - nucleus accumbens | |||
| Pathways in cancer | 48 | 3.7 | 3.50E-06 |
| TGF-beta signaling pathway | 21 | 1.6 | 1.90E-05 |
| Endocytosis | 31 | 2.4 | 3.30E-04 |
| Cell cycle | 21 | 1.6 | 4.40E-03 |
| MAPK signaling pathway | 31 | 2.4 | 3.00E-02 |
| Hypertrophic cardiomyopathy (HCM) | 14 | 1.1 | 4.90E-02 |
| Colorectal cancer | 14 | 1.1 | 5.20E-02 |
| Adipocytokine signaling pathway | 12 | 0.9 | 5.00E-02 |
| Ubiquitin mediated proteolysis | 18 | 1.4 | 7.50E-02 |
| Cytokine-cytokine receptor interaction | 27 | 2.1 | 7.30E-02 |
| Cell adhesion molecules (CAMs) | 19 | 1.5 | 9.70E-02 |
| Prostate cancer | 13 | 1 | 1.20E-01 |
| Renal cell carcinoma | 11 | 0.8 | 1.30E-01 |
| Focal adhesion | 22 | 1.7 | 1.20E-01 |
| Dilated cardiomyopathy | 13 | 1 | 1.10E-01 |
| Insulin signaling pathway | 17 | 1.3 | 1.10E-01 |
| Bladder cancer | 8 | 0.6 | 1.20E-01 |
| Hematopoietic cell lineage | 12 | 0.9 | 1.20E-01 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 11 | 0.8 | 1.40E-01 |
| Chronic myeloid leukemia | 11 | 0.8 | 1.40E-01 |
| Adherens junction | 11 | 0.8 | 1.40E-01 |
| Wnt signaling pathway | 17 | 1.3 | 1.60E-01 |
| Heparan sulfate biosynthesis | 6 | 0.5 | 1.60E-01 |
| Acute myeloid leukemia | 9 | 0.7 | 1.50E-01 |
| Type II diabetes mellitus | 8 | 0.6 | 1.90E-01 |
| Melanoma | 10 | 0.8 | 1.80E-01 |
| Thyroid cancer | 6 | 0.5 | 1.80E-01 |
| ECM-receptor interaction | 11 | 0.8 | 1.80E-01 |
| ErbB signaling pathway | 11 | 0.8 | 2.20E-01 |
| Glioma | 9 | 0.7 | 2.20E-01 |
| mTOR signaling pathway | 8 | 0.6 | 2.30E-01 |
| Chemokine signaling pathway | 18 | 1.4 | 2.70E-01 |
| Axon guidance | 14 | 1.1 | 2.80E-01 |
| Long-term potentiation | 9 | 0.7 | 2.90E-01 |
| Pancreatic cancer | 9 | 0.7 | 3.20E-01 |
| SNARE interactions in vesicular transport | 6 | 0.5 | 3.30E-01 |
| Gap junction | 10 | 0.8 | 3.30E-01 |
| NOD-like receptor signaling pathway | 8 | 0.6 | 3.30E-01 |
| Melanogenesis | 11 | 0.8 | 3.30E-01 |
| GO terms for putative target genes - nucleus accumbens | |||
| Regulation of gene expression | 276 | 21.3 | 1.80E-12 |
| Regulation of transcription | 252 | 19.5 | 2.10E-11 |
| Regulation of transcription, DNA-dependent | 170 | 13.1 | 1.40E-07 |
| Positive regulation of gene expression | 72 | 5.6 | 2.90E-06 |
| Positive regulation of transcription | 70 | 5.4 | 4.60E-06 |
| Organ morphogenesis | 80 | 6.2 | 1.60E-05 |
| Embryonic organ development | 40 | 3.1 | 1.90E-04 |
| Tissue development | 78 | 6 | 7.00E-04 |
| Positive regulation of cell differentiation | 29 | 2.2 | 4.80E-03 |
| Heart growth | 3 | 0.2 | 6.50E-01 |
Predicted pathways and gene ontology (GO) terms of differentially expressed miRNA target genes from NA analyzed through DAVID. No. of genes and percent of genes; number of genes out of all putative target genes generated through Genespring software included in respective KEGG pathway or GO term category.
KEGG pathways and GO terms for EDL putative target genes
| No. of genes included | % of genes included | ||
|---|---|---|---|
| KEGG pathways for putative target genes - EDL | |||
| Oocyte meiosis | 9 | 1.6 | 9.50E-01 |
| Pathways in cancer | 17 | 3.1 | 9.00E-01 |
| GnRH signaling pathway | 7 | 1.3 | 9.70E-01 |
| Basal transcription factors | 4 | 0.7 | 9.30E-01 |
| Prion diseases | 4 | 0.7 | 9.20E-01 |
| GO terms for putative target genes - EDL | |||
| Tissue development | 33 | 5.9 | 6.00E-01 |
| Regulation of transmission of nerve impulse | 10 | 1.8 | 7.10E-01 |
| Protein targeting | 11 | 2 | 7.50E-01 |
| Regulation of neurological system process | 10 | 1.8 | 7.00E-01 |
| Regulation of programmed cell death | 28 | 5 | 7.50E-01 |
| Neurogenesis | 27 | 4.9 | 7.40E-01 |
| Regulation of synaptic transmission | 9 | 1.6 | 7.00E-01 |
| Neuromuscular synaptic transmission | 4 | 0.7 | 7.10E-01 |
| Spinal cord motor neuron differentiation | 4 | 0.7 | 7.60E-01 |
| Generation of neurons | 24 | 4.3 | 7.60E-01 |
| Tissue morphogenesis | 14 | 2.5 | 7.60E-01 |
| Central nervous system development | 19 | 3.4 | 7.60E-01 |
| Neuron development | 16 | 2.9 | 7.50E-01 |
| Neuron projection development | 13 | 2.3 | 7.40E-01 |
| Epithelial cell differentiation | 9 | 1.6 | 7.30E-01 |
| Spinal cord development | 5 | 0.9 | 7.80E-01 |
| Hemopoietic progenitor cell differentiation | 3 | 0.5 | 7.70E-01 |
| Water transport | 3 | 0.5 | 7.70E-01 |
| Cellular protein metabolic process | 75 | 13.5 | 7.90E-01 |
| Axonogenesis | 10 | 1.8 | 7.90E-01 |
| Ion homeostasis | 15 | 2.7 | 7.80E-01 |
| Neuron migration | 6 | 1.1 | 7.90E-01 |
| Positive regulation of dopamine secretion | 2 | 0.4 | 7.80E-01 |
| Hemopoiesis | 13 | 2.3 | 8.00E-01 |
| Neuron projection morphogenesis | 10 | 1.8 | 8.20E-01 |
| Synaptic transmission | 10 | 1.8 | 8.30E-01 |
| Positive regulation of actin filament depolymerization | 2 | 0.4 | 8.30E-01 |
| Positive regulation of integrin activation | 2 | 0.4 | 8.30E-01 |
| Positive regulation of catecholamine secretion | 2 | 0.4 | 8.30E-01 |
| Unsaturated fatty acid metabolic process | 4 | 0.7 | 8.40E-01 |
| Cell morphogenesis involved in neuron differentiation | 10 | 1.8 | 8.40E-01 |
Predicted pathways and gene ontology (GO) terms of differentially expressed miRNA target genes in EDL analyzed through DAVID. No. of genes and percent of genes; number of genes out of all putative target genes generated through Genespring software included in respective KEGG pathway or GO term category.